Evaluation of the Effect of Botulinum Toxin A on the Lymphatic Endothelial Cells
Open Access
- 5 June 2024
- journal article
- research article
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 48 (21) , 4513-4522
Abstract
Introduction: Botulinum toxin A (BoTA) is a neurotoxin formed by Clostridium botulinum, with a broad medical application spectrum. While the primary effect of BoTA is on the muscles, the effects of BoTA in other systems including the blood vasculature have already been examined, revealing unexpected actions. However, no studies exist to the best of our knowledge regarding the potential effects of BoTA on the lymphatic vascular system, possessing a critical role in health and disease. Isolated human lymphatic endothelial cells (LECs) were cultured in dedicated in vitro culture systems. The analysis including imaging and cell culture approaches as well as molecular biology techniques is performed to examine the LEC alterations occurring upon exposure to different concentrations of BoTA. Materials and Methods: Human LECs were cultured and expanded on collagen-coated petri dishes using endothelial basal medium and the commercial product Botox from Allergan as used for all our experiments. Harvested cells were used in various in vitro functional tests to assess the morphologic and functional properties of the BoTA-treated LECs. Gene expression analysis was performed to assess the most important lymphatic system-related genes and pathways. Results: Concentrations of 1, 5 or 10 U of BoTA did not demonstrate a significant effect regarding the proliferation and migration capacity of the LECs versus untreated controls. Interestingly, even the smallest BoTA dose was found to significantly decrease the cord-like-structure formation capacity of the seeded LECs. Gene expression analysis was used to underpin possible molecular alterations, suggesting no significant effect of BoTA in the modification of gene expression versus the starvation medium control. Conclusion: LECs appear largely unaffected to BoTA treatment, with an isolated effect on the cord-like-structure formation capacity. Further work needs to assess the effect of BoTA on the smooth-muscle-cell-covered collecting lymphatic vessels and the possible aesthetic implications of such an effect, due to edema formation. Level of Evidence V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (KI 1973/2-1)
- Lipedema Foundation (27A, 56)
- Sassella Foundation (19/15, 2021/13)
- Novartis Stiftung für Medizinisch-Biologische Forschung (22A038, 22A046)
- University of Zurich
This publication has 42 references indexed in Scilit:
- Botulinum Toxin A Treatment of Raynaud's Phenomenon: A ReviewSeminars in Arthritis and Rheumatism, 2012
- The effects of botulinum toxin A on the survival of a random cutaneous flapJournal of Plastic, Reconstructive & Aesthetic Surgery, 2009
- The effect of botulinum toxin A on skin flap survival in ratsWound Repair and Regeneration, 2009
- Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scarJournal of Plastic, Reconstructive & Aesthetic Surgery, 2008
- Reduction of lymphatic vessels in photodamaged human skinJournal of Dermatological Science, 2007
- Botulinum Toxin a in the Treatment of SialorrheaAnnals of Pharmacotherapy, 2007
- The use of botulinum toxin therapy for lower-extremity spasticity in children with cerebral palsyNeurosurgical Focus, 2006
- Use of Botulinum Toxin Type A to Prevent Widening of Facial ScarsPlastic and Reconstructive Surgery, 2006
- Treatment of Recalcitrant Idiopathic Muscular Torticollis in Infants with Botulinum Toxin Type AJournal of Craniofacial Surgery, 2005
- The action of botulinum toxin on the neuro‐muscular junctionThe Journal of Physiology, 1949